Worldwide Biotech/Biopharma Alliance (May 22, 2013～May 15, 2013)
On May 22, 2013, Agilent Technologies Inc., the Glyco-MEV laboratory at the University of Rouen, and Technology and Research (A*STAR) in Singapore signed a memorandum of understanding to work together to develop tools to effectively analyze biologics and vaccines. The biologics include molecules such as antibodies, growth factors and other recombinant protein based therapeutics, together with vaccines are used to prevent or treat a variety of serious medical conditions affecting millions of people annually such as cancers, immune disorders and infectious diseases.These therapeutic agents are typically produced by bioprocesses using living cells as factories for their production.
On May 21, 2013, Pfizer and Merck each announced major China drug JVs with domestic China pharmas – Hisun in Pfizer’s case and Simcere for Merck. The arrangements were high-profile, and their aims went beyond drug distributorship, reaching into drug development.
On May 21, 2013, A*STAR’s Genome Institute of Singapore signed an agreement with QuantuMDx. Under this collaboration, QMDx’s wholly owned Singapore-based subsidiary QMDx Asia and GIS will develop Asia-specific point-of-care genetic tests for use with Q-POC™, QMDx’s handheld point-of-care device. QMDx will commercialize the tests. The first assay from the development pipeline will direct treatment of East Asian patients with kinase-driven cancers, such as chronic myeloid leukemia (CML) and epidermal growth factor receptor-mutated non-small lung cancer (EGFR NSCLC).
On May 16, 2013, DBV Technologiesand Stallergenes S.A.announced that they have entered into a strategic research partnership. This partnership combines Stallergenes' expertise in respiratory allergies with DBV's Viaskin. DBV will conduct all preclinical work, up to proof-of-concept studies using Viaskin® and Stallergenes' aeroallergens. Stallergenes will finance all of DBV's research on these aeroallergens and will have development and commercialization rights. In the coming months, the parties will enter into license agreements for each aeroallergen, defining the opt-in terms for development and commercialization.
On May 15, 2013, The Almac biocatalysis group secured a BBSRC (Biotechnology and Biological Sciences Research Council) programme with UCL focused specifically on metagenomics and novel enzyme discovery. The R&D work concerned is set to be carried out jointly between Almac and the departments of Biochemical Engineering and Chemistry at UCL, with high level input from two world leaders in the field of biocatalyst discovery and application.